Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19294125 | 0.92 | MAPT (0.36) | MAPTAPPMEN1ALDH1A1KMT2A | |
| SCHEMBL18220163 | 0.91 | MAPT (0.36) | MAPTAPPMEN1ALDH1A1KMT2A | |
| SCHEMBL19294126 | 0.91 | MAPT (0.35) | MAPTAPPSCN9A | |
| SCHEMBL18220159 | 0.84 | MAPT (0.37) | MAPTAPPMEN1ALDH1A1KMT2A | |
| SCHEMBL19294130 | 0.84 | MAPT (0.43) | MAPTAPPMEN1ALDH1A1KMT2A | |
| SCHEMBL18220269 | 0.83 | MAPT (0.36) | MAPTAPP | |
| SCHEMBL18220158 | 0.83 | MAPT (0.36) | MAPTAPPMEN1ALDH1A1KMT2A | |
| SCHEMBL26229681 | 0.82 | APP (0.43) | MAPTAPPMEN1ALDH1A1KMT2A | |
| SCHEMBL24068151 | 0.82 | MEN1 (0.33) | MAPTMEN1ALDH1A1KMT2APSMD14 | |
| SCHEMBL18221503 | 0.82 | MAPT (0.34) | MAPTAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | MAPT 25/4885APP 1/4885MEN1 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.